MIC
ABBV icon

Means Investment Company’s AbbVie ABBV Stock Holding History

Means Investment Company’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.09M Sell
23,421
-609
-3% -$135K 0.44% 35
2025
Q4 		$5.49M Sell
24,030
-1,445
-6% -$329K 0.46% 33
2025
Q3 		$5.9M Sell
25,475
-1,376
-5% -$280K 0.51% 29
2025
Q2 		$4.98M Buy
26,851
+19
+0.1% +$3.53K 0.47% 35
2025
Q1 		$5.62M Sell
26,832
-847
-3% -$165K 0.6% 29
2024
Q4 		$4.92M Sell
27,679
-18
-0.1% -$3.31K 0.51% 35
2024
Q3 		$5.47M Buy
27,697
+143
+0.5% +$26.7K 0.61% 32
2024
Q2 		$4.73M Sell
27,554
-1,789
-6% -$296K 0.57% 33
2024
Q1 		$5.34M Sell
29,343
-197
-0.7% -$34K 0.69% 28
2023
Q4 		$4.58M Buy
29,540
+106
+0.4% +$15.5K 0.66% 27
2023
Q3 		$4.39M Sell
29,434
-78
-0.3% -$11.5K 0.72% 25
2023
Q2 		$3.98M Sell
29,512
-64
-0.2% -$9.38K 0.63% 31
2023
Q1 		$4.71M Buy
29,576
+98
+0.3% +$15K 0.83% 27
2022
Q4 		$4.76M Buy
29,478
+77
+0.3% +$11.8K 0.95% 25
2022
Q3 		$3.95M Sell
29,401
-402
-1% -$57.7K 0.86% 23
2022
Q2 		$4.57M Sell
29,803
-216
-0.7% -$33K 0.97% 23
2022
Q1 		$4.87M Buy
30,019
+50
+0.2% +$7.26K 0.88% 22
2021
Q4 		$4.06M Buy
29,969
+80
+0.3% +$9.45K 0.72% 26
2021
Q3 		$3.22M Sell
29,889
-45
-0.2% -$5.14K 0.64% 33
2021
Q2 		$3.37M Buy
29,934
+226
+0.8% +$25.5K 0.67% 31
2021
Q1 		$3.21M Buy
29,708
+189
+0.6% +$20.2K 0.73% 29
2020
Q4 		$3.06M Buy
29,519
+1,045
+4% +$100K 0.7% 28
2020
Q3 		$2.64M Sell
28,474
-175
-0.6% -$16.5K 0.73% 33
2020
Q2 		$2.65M Buy
28,649
+205
+0.7% +$18K 0.83% 29
2020
Q1 		$2.32M Sell
28,444
-118
-0.4% -$10.1K 0.9% 31
2019
Q4 		$2.51M Sell
28,562
-238
-0.8% -$19.8K 0.84% 34
2019
Q3 		$2.39M Buy
28,800
+13
+0% +$891 0.9% 34
2019
Q2 		$2.05M Sell
28,787
-863
-3% -$67.8K 0.84% 39
2019
Q1 		$2.39M Buy
29,650
+10,307
+53% +$843K 1.05% 28
2018
Q4 		$1.78M Buy
+19,343
New +$1.7M 0.99% 30

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Means Investment Company's ABBV Position: Q1 2026 in Review

Means Investment Company reduced its AbbVie (ABBV) stake by 2.5% in Q1 2026, selling an estimated $135K and leaving 23,421 shares worth $5.09M. The position accounts for 0.44% of the portfolio, ranked #35.

Means Investment Company first reported a position in ABBV in Q4 2018 and has held it in 30 quarters since. The position peaked at $5.9M in Q3 2025. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Means Investment Company held 23,421 shares of AbbVie worth $5.09M as of Q1 2026.
  • Means Investment Company sold 609 AbbVie shares in Q1 2026, an estimated $135K.
  • AbbVie made up 0.44% of Means Investment Company's portfolio in Q1 2026, its #35 holding.
  • Means Investment Company first reported a position in AbbVie in Q4 2018 and has held it in 30 quarters since.
  • Means Investment Company's AbbVie position peaked at $5.9M in Q3 2025.
  • 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Means Investment Company's 13F filing for Q1 2026, filed 24 Apr 2026.